Nisha Lassi Jacobs MD
Gastrointestinal Cancer, Hematologic Oncology
Attending physician Director of medical oncology at Mercy Hospital Site Medical Director for Minnesota Oncology—Coon Rapids
Join to View Full Profile
11850 Blackfoot St NeSuite 100Coon Rapids, MN 55433
Phone+1 763-712-2100
Fax+1 763-712-2190
Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified medical oncologist, hematologist, and coagulation specialist. I completed my training at the Mayo Clinic and University of Minnesota. My specific interests include gastrointestinal malignancies, in particular colorectal cancer, pancreatic cancer, and hepatobiliary malignancies
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2009 - 2012
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2006 - 2009
University of Missouri Kansas City School of MedicineClass of 2006
Certifications & Licensure
MN State Medical License 2007 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsA Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, Todd C Skaar, Jeffrey L Berenberg
Clinical Cancer Research. 2024-07-01 - 4 citationsPreemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.Aminah Jatoi, Fang-Shu Ou, Daniel H. Ahn, Tyler Zemla, Jennifer Le-Rademacher
The Oncologist. 2021-07-01 - 173 citationsRegorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.Tanios Bekaii-Saab, Fang-Shu Ou, Daniel H. Ahn, Patrick McKay Boland, Kristen K. Ciombor
The Lancet. Oncology. 2019-08-01
Books/Book Chapters
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Hindi, German, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
